← Back to Search

Exemestane for Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Led By Manish Patel, DO
Research Sponsored by Masonic Cancer Center, University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year after enrollment
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a therapy called exemestane in post-menopausal women with advanced lung cancer who have not responded to other treatments. Exemestane works by lowering estrogen levels, which can help slow down the growth of cancer cells.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year after enrollment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year after enrollment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Disease Response (RECIST)
Secondary study objectives
Progression-free Survival
Quality of Life Assessment
Toxicity Assessment

Side effects data

From 2021 Phase 3 trial • 693 Patients • NCT02028507
63%
Neutrophil count decreased
55%
Fatigue
34%
Hypertension
27%
Mucositis
24%
Nausea
22%
Weight gain
20%
Diarrhea
20%
Arthralgia
19%
Upper respiratory infection
19%
Hypothermia
19%
Weight loss
18%
Vomiting
17%
Headache
15%
Anorexia
15%
Back pain
15%
Constipation
15%
Pruritus
14%
Cough
12%
Dyspepsia
12%
Bone pain
11%
Abdominal pain
11%
Fever
10%
Alopecia
10%
Flu like symptoms
10%
Pain
10%
Hot flashes
8%
Dizziness
8%
Obesity
8%
Pain in extremity
6%
Anemia
6%
Dysgeusia
5%
Palmar-plantar erythrodysesthesia syndrome
5%
Nail disorder
2%
Respiratory infection
1%
Catheter related infection
1%
Urinary tract infection
1%
Bone fracture
1%
Stroke
1%
Acidosis
1%
Suicide attempt
1%
Heart failure
1%
Lymphedema
1%
Dyspnea
1%
Pneumonitis
1%
Hip replacement
1%
Tooth infection
1%
Uveitis
1%
Respiratory failure
1%
Febrile neutropenia
1%
Hematoma
1%
Non-cardiac chest pain
1%
Sepsis
1%
Urinary bladder carcinoma
1%
Hypercalcemia
1%
Bacteremia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cohort 1: Palbociclib Plus Exemestane
Cohort 1 and 2: Capecitabine
Cohort 2: Palbociclib Plus Fulvestrant

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Exemestane TherapyExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exemestane
2003
Completed Phase 4
~7510

Find a Location

Who is running the clinical trial?

Masonic Cancer Center, University of MinnesotaLead Sponsor
279 Previous Clinical Trials
15,575 Total Patients Enrolled
Manish Patel, DOPrincipal InvestigatorUniversity of Minnesota Masonic Cancer Center
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top